News that BlackRock, the world’s biggest asset manager is reviewing the cryptocurrency industry has opened up opportunities for many investors and ICOs.
In healthcare technology, Curaizon – a pioneer of medicine adherence technologies is currently running its CuraToken (CTKN) sale to further develop and enhance its unique offering to national health services around the world. Curaizon’s token provides three distinct solutions in one – namely, CuraServe, CuraView and CuraData.
CuraServe is a complete healthcare ecosystem that increases medicine adherence to benefit both patients and healthcare providers. Using a series of outreach tools and messages, it is supported by predictive modelling and behavioural analytics to increase the rate of drug adherence. Healthcare providers can then integrate CuraView within their health services’ legacy systems to ensure that all patient data is current. This enables real-time feedback to electronic medical records.
While CuraServe and CuraView assists patients and providers, it also generates a vast amount of patient data. The standardised data is then anonymised and made available through CuraData. CuraData collects unique and valuable information, only holding demographic and adherence data with patient identifiers held by each respective national health service. The only way that pharmaceutical companies, academics and researchers can access this data by purchasing CuraTokens.
Worldwide medicine non-adherence currently stands at 50 percent, costing around $700 billion annually. These statistics clearly indicate that increasing the rate of adherence must be a priority for national health services in order to provide patients with better and effective care, more efficiently.
With CuraToken, Curaizon will deliver a value-based approach to a simple, accessible, yet valuable exchange of data and analysis that will revolutionize healthcare.
Disclaimer: BTCManager does not endorse any content or product on this page. While we aim at providing you all important information that we could obtain, readers should do their own research before taking any actions related to the company and carry full responsibility for their decisions, nor this article can be considered as investment advice.